These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27442378)

  • 21. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A; Rumi MG; Colombo M
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the future of ribavirin therapy for hepatitis C?
    Koh C; Liang TJ
    Antiviral Res; 2014 Apr; 104():34-9. PubMed ID: 24468277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to optimize current treatment of genotype 2 hepatitis C virus infection.
    Marciano S; Gadano AC
    Liver Int; 2014 Feb; 34 Suppl 1():13-7. PubMed ID: 24373073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C eradication: A long way to go.
    Waheed Y
    World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.
    Dobrowolska K; Brzdęk M; Rzymski P; Flisiak R; Pawłowska M; Janczura J; Brzdęk K; Zarębska-Michaluk D
    Expert Opin Pharmacother; 2024 May; 25(7):833-852. PubMed ID: 38768013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
    Casey JL; Feld JJ; MacParland SA
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic hepatitis C infection--eradication of the virus].
    Ben Ari Z
    Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
    El Sayed A; Barbati ZR; Turner SS; Foster AL; Morey T; Dieterich DT; Fierer DS;
    HIV Clin Trials; 2017 Mar; 18(2):60-66. PubMed ID: 28183221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness evaluation of hepatitis C therapy in Lahore.
    David YJ; Tahir A; Riaz M
    Pak J Pharm Sci; 2017 Nov; 30(6):2233-2237. PubMed ID: 29175794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.